中草药

小檗碱的药理作用及其作用机制研究进展

PDF下载

中草药 | 综述 2026,57(15): 6183-6200

收起

中草药 |综述 2026 , 57 (15) : 6183 -6200

小檗碱的药理作用及其作用机制研究进展

全屏

赵晓静¹, 陆珊¹, 张天柱¹, 雷慧玲¹, 李俊仪¹, 尹响利¹, 木廷赛尔·买买提托合提¹, 赵崇军¹, 吴嘉瑞¹

作者信息

通讯作者:

赵崇军

作者简介:

赵晓静: 赵晓静，硕士研究生，从事中药安全性评价研究。E-mail:13937830653@163.com

Advances in pharmacological action and mechanism of berberine

ZHAO Xiaojing, LU Shan, ZHANG Tianzhu, LEI Huiling, LI Junyi, YIN Xiangli, MAIMAITITUOHETI Mutingsaier, ZHAO Chongjun, WU Jiarui

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.15.033

文章导航

摘要

收起

小檗碱是一种从黄连、黄柏等传统药用植物中提取的异喹啉类生物碱，拥有悠久的临床应用历史。近年来研究证实，小檗碱在降血糖、调血脂、抗肿瘤、心血管保护、抗炎及神经保护等方面展现出多种药理活性，但现有研究成果较为分散，缺乏系统性整合。系统综述小檗碱的主要药理作用及其相关分子机制，旨在阐明其多效性背后的共同调控网络，为其临床转化与创新药物研发提供重要理论支撑。小檗碱的药理作用主要通过三大关键通路协同实现：抑制核因子-κB（nuclear factor-κB，NF-κB）和丝裂原活化蛋白激酶（mitogen activated protein kinase，MAPK）信号通路以阻断炎症级联反应；激活核因子E2相关因子2/抗氧化反应元件（nuclear factor erythroid 2-related factor 2/antioxidant response element，Nrf2/ARE）途径以增强抗氧化防御；抑制NOD样受体热蛋白结构域相关蛋白3（NOD-like receptor family pyrin domain containing protein 3，NLRP3）炎症小体组装从而减少细胞焦亡。不仅为深入理解小檗碱的药理作用机制绘制了清晰的分子图谱，也为炎症、氧化应激及细胞程序性死亡相关疾病的药物靶点开发与多通路协同治疗策略设计奠定了科学基础，具有重要的理论价值与转化前景。

关键词

小檗碱 / 脏器损伤 / 代谢性疾病 / 炎症 / 降血糖 / 调血脂作用 / 抗肿瘤 / 心血管保护 / 抗炎 / 神经保护

Abstract

收起

Berberine (BBR) is an isoquinoline alkaloid extracted from traditional medicinal plants such as Coptis chinensis and Phellodendron amurense, with a long history of clinical application. Recent studies have demonstrated that BBR exhibits multifaceted pharmacological activities, including blood glucose lowering, lipid regulation, anti-tumor effects, cardiovascular protection, anti-inflammation, and neuroprotection. However, existing research findings are relatively scattered and lack systematic integration. This article aims to systematically review the main pharmacological effects of BBR and its related molecular mechanisms, intending to elucidate the common regulatory network underlying its multifaceted effects and provide important theoretical support for its clinical translation and the development of innovative drugs. The results indicated that the multifaceted pharmacological effects of BBR are mainly achieved through the coordination of three key pathways: inhibiting the nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways to block inflammatory cascade reactions; activating the nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) pathway to enhance antioxidant defenses; and suppressing the assembly of the NOD-like receptor family, pyrin domain containing protein 3 (NLRP3) inflammasome to reduce cell pyroptosis. This study not only provides a clear molecular map for an in-depth understanding of the systemic pharmacological mechanisms of BBR, but also lays a scientific foundation for the development of drug targets and multi-pathway synergistic treatment strategies for diseases related to inflammation, oxidative stress, and programmed cell death, possessing significant theoretical value and translational prospects.

Key words

berberine / organ injury / metabolic diseases / inflammation / hypoglycemic effect / lipid-regulating effect / antitumor / cardiovascular protection / anti-inflammatory / neuroprotective

引用本文

赵晓静, 陆珊, 张天柱, 雷慧玲, 李俊仪, 尹响利, 木廷赛尔·买买提托合提, 赵崇军, 吴嘉瑞. 小檗碱的药理作用及其作用机制研究进展. 中草药, 2026 , 57 (15) : 6183 -6200 . DOI: 10.7501/j.issn.0253-2670.2026.15.033

ZHAO Xiaojing, LU Shan, ZHANG Tianzhu, LEI Huiling, LI Junyi, YIN Xiangli, MAIMAITITUOHETI Mutingsaier, ZHAO Chongjun, WU Jiarui. Advances in pharmacological action and mechanism of berberine[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (15) : 6183 -6200 . DOI: 10.7501/j.issn.0253-2670.2026.15.033

基金

收起

中央高校基础研究业务费专项——北京中医药大学基础研究基金（揭榜挂帅）项目 (2024-JYB-JBZD-051)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Song Y N, Zhang F, He Y, et al. Berberine inhibits protein citrullination of fibroblast-like synoviocytes by suppressing autophagy via STAT3/PAD4 pathway [J]. Phytomedicine, 2026, 150: 157706.
Li Z Q, Chen M L, Wang Z Y, et al. Berberine inhibits RA-FLS cell proliferation and adhesion by regulating RAS/MAPK/FOXO/HIF-1 signal pathway in the treatment of rheumatoid arthritis [J]. Bone Joint Res, 2023, 12(2): 91-102.
陈美琳, 李芝奇, 范琦琦, 等. 小檗碱药理作用及其相关作用机制研究进展[J]. 中草药, 2022, 53(18): 5861-5872.
Jiang S, Li H Q, Zhang L, et al. Generic Diagramming Platform (GDP): A comprehensive database of high-quality biomedical graphics [J]. Nucleic Acids Res, 2025, 53(D1): D1670-D1676.
Si Z Z, Zou C J, Mei X, et al. Targeting neuroinflammation in Alzheimer’s disease: From mechanisms to clinical applications [J]. Neural Regen Res, 2023, 18(4): 708-715.
孙元芳, 赖嘉敏, 王永宽, 等. 基于“肾脑相济”理论探讨安神补脑液防治阿尔茨海默病[J]. 中草药, 2024, 55(16): 5692-5703.
Lai G G, Wu H, Yang K X, et al. Potential applications of natural components of traditional Chinese medicine delivery via nanoparticle drug delivery systems in the treatment of Alzheimer’s disease [J]. Int J Nanomed, 2025, 20: 7781-7810.
Sun C B, Sha S, Shan Y B, et al. Intranasal delivery of BACE1 siRNA and berberine via engineered stem cell exosomes for the treatment of Alzheimer’s disease [J]. Int J Nanomedicine, 2025, 20: 5873-5891.
Yang Y, Wu J W, Jia L P, et al. Berberine modulates microglial polarization by activating TYROBP in Alzheimer’s disease [J]. Phytomedicine, 2024, 135: 156237.
闫丽爽, 李全, 张健, 等. 小檗碱防治阿尔茨海默病作用机制研究进展[J]. 中华中医药学刊, 2025, 43(10): 195-201.
Wang C L, Zou Q, Pu Y S, et al. Berberine rescues D-ribose-induced Alzheimer’s pathology via promoting mitophagy [J]. Int J Mol Sci, 2023, 24(6): 5896.
Li X, Meng S Y, Liu J Y, et al. Berberine ameliorates postoperative cognitive dysfunction in aged mice and regulates the PI3K-AKT pathway: A network pharmacology study [J]. J Cell Mole Med, 2025, 29(15): e70744.
Li X L, Chen J F, Feng W N, et al. Berberine ameliorates iron levels and ferroptosis in the brain of 3×Tg-AD mice [J]. Phytomedicine, 2023, 118: 154962.
周儒奎, 刘晋芳, 杨李旺, 等. 小檗碱对阿尔茨海默病小鼠学习记忆功能及前额叶皮层中BDNF和TrkB的影响[J]. 中国老年学杂志, 2025, 45(16): 4030-4034.
Patil S P, Kuehn B R. Discovery of small molecule glycolytic stimulants for enhanced ApoE lipidation in Alzheimer’s disease cell model [J]. Pharmaceuticals, 2024, 17(4): 491.
Sun C B, Dong S S, Chen W W, et al. Berberine alleviates Alzheimer’s disease by regulating the gut microenvironment, restoring the gut barrier and brain-gut axis balance [J]. Phytomedicine, 2024, 129: 155624.
Wang H J, Wu W S, Zheng Q Y, et al. Berberine alleviates sevoflurane anesthesia-induced cognitive dysfunction in neonatal mice via regulating CREB1[J]. Discov Med, 2024, 36(188): 1880-1890.
Hajipour S, Farbood Y, Dianat M, et al. Effect of berberine against cognitive deficits in rat model of thioacetamide-induced liver cirrhosis and hepatic encephalopathy (behavioral, biochemical, molecular and histological evaluations) [J]. Brain Sci, 2023, 13(6): 944.
Ma W B, Regenthal R, Krügel U. Natural compounds and their potential in eating-related aspects of mental health disorders [J]. Nutrients, 2025, 17(14): 2383.
Gao Y, Nie K X, Wang H Z, et al. Research progress on antidepressant effects and mechanisms of berberine [J]. Front Pharmacol, 2024, 15: 1331440.
Chen C Y, Zhang Y. Berberine: An isoquinoline alkaloid targeting the oxidative stress and gut-brain axis in the models of depression [J]. Eur J Med Chem, 2025, 290: 117475.
郑涛, 吕志阳. 小檗碱对创伤后应激障碍大鼠抑郁焦虑样行为的影响[J]. 中国工业医学杂志, 2025, 38(4): 441-445.
Yang L, Huang Y Z, Chen F X, et al. Berberine attenuates depression-like behavior by modulating the hippocampal NLRP3 ubiquitination signaling pathway through Trim65[J]. Int Immunopharmacol, 2023, 123: 110808.
Ge P Y, Qu S Y, Ni S J, et al. Berberine ameliorates depression-like behavior in CUMS mice by activating TPH1 and inhibiting IDO1-associated with tryptophan metabolism [J]. Phytother Res, 2023, 37(1): 342-357.
Tang Y H, Su H, Nie K X, et al. Berberine exerts antidepressant effects in vivo and in vitro through the PI3K/AKT/CREB/BDNF signaling pathway [J]. Biomed Pharmacother, 2024, 170: 116012.
He M, Chen Y X, Feng P P, et al. Berberine alleviates chronic pain-induced anxiety-like behaviors by inhibiting the activation of VLT-projecting cACC (Cg2) neurons [J]. Commun Biol, 2024, 7(1): 1651.
Liu Z M, Zhang X L, Sun Y L, et al. Berberine improves depression-like behaviors and gastrointestinal dysfunction in 6-hydroxydopamine-induced Parkinson’s disease rats [J]. Neurogastroenterol Motil, 2025, 37(7): e70033.
Ding W L, Gu Q C, Liu M M, et al. Astrocytes-derived exosomes pre-treated by berberine inhibit neuroinflammation after stroke via miR-182-5p/Rac1 pathway [J]. Int Immunopharmacol, 2023, 118: 110047.
Sun C B, Gao X Y, Sha S, et al. Berberine alleviates Alzheimer’s disease by activating autophagy and inhibiting ferroptosis through the JNK-p38MAPK signaling pathway [J]. Int Immunopharmacol, 2025, 155: 114550.
Sun J, Zeng Q H, Wu Z M, et al. Berberine inhibits NLRP3 inflammasome activation and proinflammatory macrophage M1 polarization to accelerate peripheral nerve regeneration [J]. Neurotherapeutics, 2024, 21(4): e00347.
Alshahrani S M, Al-kuraishy H M, Al-Gareeb A I, et al. Berberine’s paradox in Neurodegeneration: Therapeutic promise and safety challenges in Parkinson’s disease [J]. Neuropharmacology, 2025, 278: 110555.
Tseng H C, Wang M H, Fang C H, et al. Neuroprotective potentials of berberine in rotenone-induced Parkinson’s disease-like motor symptoms in rats [J]. Brain Sci, 2024, 14(6): 596.
赵海港, 吴斌, 梁亚丽, 等. 小檗碱通过抑制CDK5/ P25表达逆转MMP⁺诱导帕金森病细胞模型损伤[J]. 中国临床神经科学, 2022, 30(2): 147-152.
Cha H R, Kim J S, Ryu J H, et al. Investigating neuroprotective effects of berberine on mitochondrial dysfunction and autophagy impairment in Parkinson’s disease [J]. Int J Mol Sci, 2025, 26(15): 7342.
Alsfouk B A, Al-Kuraishy H M, Albuhadily A K, et al. The potential therapeutic role of berberine in treating epilepsy focusing on temporal lobe epilepsy: State of art and ongoing perspective [J]. Brain Res Bull, 2025, 221: 111189.
Zhu H L, Wu Z Y, Yu Y Z, et al. Integrated non-targeted metabolomics and network pharmacology to reveal the mechanisms of berberine in the long-term treatment of PTZ-induced epilepsy [J]. Life Sci, 2024, 336: 122347.
Bertoncello K T, Rodrigues G, Bonan C D. Berberine and hesperidin prevent the memory consolidation impairment induced by pentylenetetrazole in zebrafish [J]. Behav Brain Res, 2024, 466: 114981.
Saha L, Kumari P, Rawat K, et al. Neuroprotective effect of berberine nanoparticles against seizures in pentylenetetrazole induced kindling model of epileptogenesis: Role of anti-oxidative, anti-inflammatory, and anti-apoptotic mechanisms [J]. Neurochem Res, 2023, 48(10): 3055-3072.
Dai W T, Zhu Y, Jiang Z M, et al. Berberine alleviates kainic acid-induced acute epileptic seizures in mice via reshaping gut microbiota-associated lipid metabolism [J]. CNS Neurosci Ther, 2025, 31(2): e70253.
穆晞园, 罗晓东, 刘守青. 小檗碱治疗奥氮平致精神分裂症患者胰岛素抵抗的疗效及对炎性因子相关蛋白的影响[J]. 现代实用医学, 2024, 36(1): 35-37.
延李科, 崔灿, 王颖, 等. 小檗碱介导钟控基因调节糖脂代谢改善肝细胞胰岛素抵抗的分子机制[J]. 中国中药杂志, 2024, 49(23): 6368-6377.
Xia Q S, Wu F, Wu W B, et al. Berberine reduces hepatic ceramide levels to improve insulin resistance in HFD-fed mice by inhibiting HIF-2α [J]. Biomed Pharmacother, 2022, 150: 112955.
李茉, 翟佳佳, 杨泽龙, 等. 小檗碱通过PTEN/Nrf2途径抑制胰岛βTC6氧化应激及细胞凋亡[J]. 现代生物医学进展, 2022, 22(21): 4035-4042.
张多加, 张明明, 王婷婷, 等. 小檗碱对多囊卵巢综合征大鼠卵巢局部胰岛素抵抗的调控作用[J]. 世界中医药, 2022, 17(17): 2429-2436.
李慕白, 王婷婷, 张多加, 等. 小檗碱改善多囊卵巢综合征伴胰岛素抵抗大鼠子宫组织局部胰岛素抵抗的作用机制研究[J]. 现代中西医结合杂志, 2022, 31(2): 153-160.
Li Y R, Chen X Q, Chen Y L, et al. Berberine improves TNF-α-induced hepatic insulin resistance by targeting MEKK1/MEK pathway [J]. Inflammation, 2022, 45(5): 2016-2026.
Chen Y, Li Q, Zhao S W, et al. Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis [J]. Biochem Pharmacol, 2023, 218: 115928.
Du J D, Zhu Y, Yang X H, et al. Berberine attenuates obesity-induced insulin resistance by inhibiting miR-27a secretion [J]. Diabet Med, 2024, 41(7): e15319.
Li A Y, Lin C, Xie F F, et al. Berberine ameliorates insulin resistance by inhibiting IKK/NF-κB, JNK, and IRS-1/AKT signaling pathway in liver of gestational diabetes mellitus rats [J]. Metab Syndr Relat Disord, 2022, 20(8): 480-488.
Liu K, Sun T T, Luan Y, et al. Berberine ameliorates erectile dysfunction in rats with streptozotocin-induced diabetes mellitus through the attenuation of apoptosis by inhibiting the SPHK1/S1P/S1PR2 and MAPK pathways [J]. Andrology, 2022, 10(2): 404-418.
陈赓, 王健, 钱小凤, 等. 小檗碱通过p38MAPK/ERK通路抑制阴茎海绵体细胞凋亡以增强糖尿病大鼠勃起功能[J]. 解剖学研究, 2022, 44(4): 313-319.
万彬彬, 张月, 何昂, 等. 小檗碱抑制JAK2/STAT3信号通路改善糖尿病大鼠前额叶皮层神经元损伤[J]. 湖北科技学院学报: 医学版, 2023, 37(4): 292-297.
Tang Y H, Gao Y, Nie K X, et al. Jiao-Tai-Wan and its effective component-berberine improve diabetes and depressive disorder through the cAMP/PKA/CREB signaling pathway [J]. J Ethnopharmacol, 2024, 324: 117829.
Yuan H Y, Wang B H, Ye Z C, et al. Berberine alleviates the damage, oxidative stress and mitochondrial dysfunction of PC12 cells induced by high glucose by activating the KEAP1/Nrf2/ARE pathway [J]. Mol Biotechnol, 2023, 65(10): 1632-1643.
牛耕, 周先炎, 陶录岭. 黄连素联合甲钴胺片治疗糖尿病脑病疗效观察及对血清miR-132-3p、miR-137表达与胰岛素抵抗的影响[J]. 新中医, 2025, 57(7): 115-119.
章时杰, 李宏英, 王奇, 等. 黄连素通过SIRT1/ER stress通路保护糖尿病脑病[J]. 神经药理学报, 2017, 7(3): 62.
Fang W Y, Huang X J, Wu K C, et al. Activation of the GABA-alpha receptor by berberine rescues retinal ganglion cells to attenuate experimental diabetic retinopathy [J]. Front Mol Neurosci, 2022, 15: 930599.
Yang Y, Wen Z X, Zhang Y L, et al. Berberine alleviates diabetic retinopathy by regulating the Th17/Treg ratio [J]. Immunol Lett, 2024, 267: 106862.
Ai X P, Yu P L, Luo L L, et al. Berberis dictyophylla F. inhibits angiogenesis and apoptosis of diabetic retinopathy via suppressing HIF-1α/VEGF/DLL-4/Notch-1 pathway [J]. J Ethnopharmacol, 2022, 296: 115453.
Li N, Chen J L, Sun Y J, et al. Berberine attenuates the expression of NLRP3 and downstream inflammasome effectors in diabetic retinopathy [J]. J Nat Med, 2025, 79(5): 1091-1105.
Zhong C S, Xie Y L, Wang H F, et al. Berberine inhibits NLRP3 inflammasome activation by regulating mTOR/ mtROS axis to alleviate diabetic cardiomyopathy [J]. Eur J Pharmacol, 2024, 964: 176253.
Chen W X, Jin T Z, Xie Y L, et al. Berberine partially ameliorates cardiolipotoxicity in diabetic cardiomyopathy by modulating SIRT3-mediated lipophagy to remodel lipid droplets homeostasis [J]. Br J Pharmacol, 2025, 182(20): 5038-5056.
Yang L, Cheng C F, Li Z F, et al. Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR-18a-3p/Gsdmd pathway [J]. Int J Mol Med, 2023, 51(6): 49.
韩俊, 彭定凤, 胡勇钧, 等. 黄连素调节miRNA126及miRNA92a减轻糖尿病心肌梗死大鼠心肌损伤[J]. 中国中西医结合杂志, 2022, 42(4): 449-454.
吴跃跃, 陈灶萍, 盛励, 等. 脂联素受体介导小檗碱减轻糖尿病肾病肾脏脂毒性[J]. 中国临床医学, 2024, 31(3): 433-439.
Wang C, Wu H, Xie Y S, et al. Berberine inhibits migration and apoptosis of rat podocytes in diabetic nephropathy via the novel lncRNA LOC102549726 related pathway [J]. Phytother Res, 2025, 39(3): 1615-1631.
赵丽, 王锁刚, 马继伟, 等. 基于“苦坚肾”理念对黄柏改善糖尿病肾病足细胞损伤的机制研究[J]. 中医研究, 2023, 36(6): 71-76.
Ni W J, Guan X M, Zeng J, et al. Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/ GLUT1 signalling pathway [J]. J Cell Mol Med, 2022, 26(4): 1144-1155.
Yang L, Yuan S M, Wang R R, et al. Exploring the molecular mechanism of berberine for treating diabetic nephropathy based on network pharmacology [J]. Int Immunopharmacol, 2024, 126: 111237.
Wang Y, Yue S, Cai F, et al. Treatment of berberine alleviates diabetic nephropathy by reducing iron overload and inhibiting oxidative stress [J]. Histol Histopathol, 2023, 38(9): 1009-1016.
Cai S Y, Zhu H Z, Chen L L, et al. Berberine inhibits KLF4 promoter methylation and ferroptosis to ameliorate diabetic nephropathy in mice [J]. Chem Res Toxicol, 2024, 37(10): 1728-1737.
Gao K, Liu Y H, Li K, et al. Nrf2-mediated ferroptosis is involved in berberine-induced alleviation of diabetic kidney disease [J]. Phytother Res, 2025, 39(12): 5604-5616.
邓礼娟, 黄洁瑶, 胡彦君, 等. 小檗碱对糖尿病肾病小鼠肾脏中FXR和SHP表达的影响[J]. 中国药理学通报, 2024, 40(12): 2269-2276.
戴宾宾, 包继文, 刘子康, 等. 小檗碱通过上调肉碱棕榈酰转移酶1α介导的脂肪酸氧化减轻糖尿病肾脏疾病肾损伤[J]. 临床肾脏病杂志, 2025, 25(8): 688-696.
Zhao Y N, Huang J F, Li T Y, et al. Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition [J]. J Cell Mol Med, 2022, 26(4): 1060-1070.
Wu C H, Yang J, Ye C X, et al. Berberine attenuates 5-fluorouracil-induced intestinal mucosal injury by modulating the gut microbiota without compromising its anti-tumor efficacy [J]. Heliyon, 2024, 10(14): e34528.
Ishiguro M, Takahara M, Takaki A, et al. Berberine prevents NSAID-induced small intestinal injury by protecting intestinal barrier and inhibiting inflammasome-associated activation [J]. Dig Dis Sci, 2025, 70(12): 4140-4151.
Yu J S, Zheng Y X, Liu C M, et al. Multi-omics reveals the alleviating effect of berberine on ulcerative colitis through modulating the gut microbiome and bile acid metabolism in the gut-liver axis [J]. Front Pharmacol, 2024, 15: 1494210.
Huang Y Q, Liu J L, Chen G X, et al. Berberine enhances intestinal mucosal barrier function by promoting vitamin D receptor activity [J]. Chin J Integr Med, 2024, 30(2): 143-151.
Feng A W, Su S S, Li C, et al. Berberine decreases S100B generation to regulate gut vascular barrier permeability in mice with burn injury [J]. Pharm Biol, 2024, 62(1): 53-61.
Qiu D Z, Zhang W, Song Z J, et al. Berberine suppresses cecal ligation and puncture induced intestinal injury by enhancing Treg cell function [J]. Int Immunopharmacol, 2022, 106: 108564.
Zhao D Y, Zhai Y, Chen C, et al. Berberine repairs intestinal mucosal barrier by targeting HSP90AA1 and MAPK14[J]. Pharmacogenomics Pers Med, 2025, 18: 263-278.
Luo Z C, Li Z H, Liang Z, et al. Berberine increases stromal production of Wnt molecules and activates Lgr5(+) stem cells to promote epithelial restitution in experimental colitis [J]. BMC Biol, 2022, 20(1): 287.
Li J L, Dan W C, Zhang C C, et al. Exploration of berberine against ulcerative colitis via TLR4/NF-κB/HIF-1α pathway by bioinformatics and experimental validation [J]. Drug Des Dev Ther, 2024, 18: 2847-2868.
Tao X Y, Gao Y F, Jin Z S, et al. Co-administration of berberine and evodiamine: Mitigating evodiamine-induced hepatotoxicity and potentiating colitis treatment [J]. Phytomedicine, 2025, 147: 157185.
Wang Y, Zhang Z T, Du M, et al. Berberine alleviates ETEC-induced intestinal inflammation and oxidative stress damage by optimizing intestinal microbial composition in a weaned piglet model [J]. Front Immunol, 2024, 15: 1460127.
Cao J W, Chen M Y, Xu R, et al. Therapeutic mechanisms of berberine to improve the intestinal barrier function via modulating gut microbiota, TLR4/NF-κ B/MTORC pathway and autophagy in cats [J]. Front Microbiol, 2022, 13: 961885.
Deng C, Zhang H X, Li Y X, et al. Exosomes derived from mesenchymal stem cells containing berberine for ulcerative colitis therapy [J]. J Colloid Interface Sci, 2024, 671: 354-373.
Yang Y X, Li W Q, Sun K N, et al. Berberine ameliorates dextran sulfate sodium-induced colitis through tuft cells and bitter taste signalling [J]. BMC Biol, 2024, 22(1): 280.
Ling Q Y, Fang J, Zhai C, et al. Berberine induces SOCS1 pathway to reprogram the M1 polarization of macrophages via miR-155-5p in colitis-associated colorectal cancer [J]. Eur J Pharmacol, 2023, 949: 175724.
Liu C, Gong Q M, Liu W N, et al. Berberine-loaded PLGA nanoparticles alleviate ulcerative colitis by targeting IL-6/IL-6R axis [J]. J Transl Med, 2024, 22(1): 963.
Xu X F, Li W, Yu Z D, et al. Berberine ameliorates dextran sulfate sodium-induced ulcerative colitis and inhibits the secretion of gut lysozyme via promoting autophagy [J]. Metabolites, 2022, 12(8): 676.
Yu H S, Zhang S B, Li R M, et al. Berberine alleviates inflammation and suppresses PLA2-COX-2-PGE2-EP2 pathway through targeting gut microbiota in DSS-induced ulcerative colitis [J]. Biochem Biophys Res Commun, 2024, 695: 149411.
Li C, Yin X X, Xie C P, et al. Berberine attenuates TNBS-induced colitis in mice by improving the intestinal microbiota [J]. Front Microbiol, 2024, 15: 1463005.
Wang X M, Liang F N, Dai Z Y, et al. Combination of Coptis chinensis polysaccharides and berberine ameliorates ulcerative colitis by regulating gut microbiota and activating AhR/IL-22 pathway [J]. J Ethnopharmacol, 2024, 318: 117050.
Sun X J, Zhang Y, Cheng G, et al. Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism [J]. Biomed Pharmacother, 2023, 167: 115430.
Du M, Liu X R, Ji X, et al. Berberine alleviates enterotoxigenic Escherichia coli-induced intestinal mucosal barrier function damage in a piglet model by modulation of the intestinal microbiome [J]. Front Nutr, 2025, 11: 1494348.
Gong Y L, Lu Q S, Liu Y L, et al. Dietary berberine alleviates high carbohydrate diet-induced intestinal damages and improves lipid metabolism in largemouth bass (Micropterus salmoides) [J]. Front Nutr, 2022, 9: 1010859.
Chen L S, Wang X, Li J Y, et al. Elucidation of the mechanism of berberine against gastric mucosa injury in a rat model with chronic atrophic gastritis based on a combined strategy of multi-omics and molecular biology [J]. Front Pharmacol, 2025, 15: 1499753.
马嘉嘉, 郑倩, 李大伟, 等. 小檗碱对幽门螺旋杆菌感染小鼠胃粘膜损伤和免疫功能的影响机制研究[J]. 现代生物医学进展, 2023, 23(11): 2019-2024.
Wang L L, Xie L Q. Berberine alleviates 1-methyl-3-nitro-1-nitrosoguanidine-induced chronic atrophic gastritis in rats [J]. Turk J Gastroenterol, 2025, 36(11): 723-731.
Zheng Y M, Chen B, Zhang M Q, et al. Autophagic degradation of LOX-1 is involved in the maintenance of vascular integrity injured by oxLDL and protected by Berberine [J]. Int J Biol Sci, 2023, 19(6): 1813-1830.
Sun J, Shi N N, Zhang X M, et al. Vanadyl acetylacetonate and berberine synergistically ameliorate diabetes-induced vascular dysfunction and reduce endothelial toxicity through ERK and Akt regulation [J]. Biol Trace Elem Res, 2026, 204(3): 1678-1692.
Hong Y, Feng J, Dou Z J, et al. Berberine as a novel ACSL4 inhibitor to suppress endothelial ferroptosis and atherosclerosis [J]. Biomed Pharmacother, 2024, 177: 117081.
Wang T T, Yu L L, Zheng J M, et al. Berberine inhibits ferroptosis and stabilizes atherosclerotic plaque through NRF2/SLC7A11/GPX4 pathway [J]. Chin J Integr Med, 2024, 30(10): 906-916.
Yang K T, Chao T H, Wang I C, et al. Berberine protects cardiac cells against ferroptosis [J]. Tzu Chi Med J, 2022, 34(3): 310-317.
Ahmedy O A, Salem H H, Mohamed Y S, et al. Unleashing the cardioprotective potential of berberine against doxorubicin cardiotoxicity: Innovative exploitation of the peculiar antipyroptotic/antioxidant/anti-inflammatory capacity via modulation of inflammasome/caspase-1/ interleukin pathway in rats [J]. Int Immunopharmacol, 2025, 159: 114964.
Wei K K, Li J M, Yu L T, et al. A combination of tetramethylpyrazine and berberine prevents coronary microembolization in rats by regulating miR-34a-5p in platelet-derived exosomes [J]. J Ethnopharmacol, 2026, 354: 120549.
Zheng J M, Wang T T, Zhou Y, et al. Berberine ameliorates atherosclerosis by inhibiting the phenotypic transition of vascular smooth muscle cells via suppression of the JAK2/STAT3 signaling pathway [J]. Eur J Pharmacol, 2025, 1007: 178234.
Li H T, Zhang Z J, Yang Y, et al. Exploring the mechanism of action of berberine on arrhythmia after myocardial infarction: A network pharmacology, molecular docking, and cellular experimental study [J]. Cardiovasc Ther, 2025, 2025: 5632985.
Li C X, Wu W T, Xing J H, et al. Berberine attenuates sunitinib-induced cardiac dysfunction by normalizing calcium regulation disorder via SGK1 activation [J]. Food Chem Toxicol, 2023, 175: 113743.
Mu Y, Geng J, Liu C L, et al. Exploring the multi-faceted effects of berberine in ameliorating diastolic dysfunction in rats with heart failure with preserved ejection fraction [J]. Int J Mol Sci, 2025, 26(10): 4847.
Zhang H, Wu X F, Tao Y Y, et al. Berberine attenuates sepsis-induced cardiac dysfunction by upregulating the Akt/ENOS pathway in mice [J]. Exp Ther Med, 2022, 23(6): 371.
Basiouny S M, Zaki H F, Elshazly S M, et al. Berberine ameliorates seizure activity and cardiac dysfunction in pentylenetetrazol-kindling seizures in rats: Modulation of sigma1 receptor, Akt/ENOS signaling, and ferroptosis [J]. Neuropharmacology, 2025, 267: 110295.
Yang H C, Cao G, Li X, et al. Berberine intervention mitigates myocardial ischemia-reperfusion injury in a rat model: Mechanistic insights via miR-184 signaling [J]. Biologics, 2025, 19: 31-42.
Zhang P, Jin M Y, Zhang L, et al. Berberine alleviates atherosclerosis by modulating autophagy and inflammation through the RAGE-NF-κB pathway [J]. Front Pharmacol, 2025, 16: 1540835.
Zhou Z J, Xu Y L, Xiao X, et al. Berberine inhibits NLRP3 inflammasome activation by upregulating the SIRT6-AMPK pathway to prevent angiotensin II-induced fibrosis and vulnerability to atrial fibrillation [J]. Int Immunopharmacol, 2026, 168: 115919.
Goto K, Fujiwara-Tani R, Nukaga S, et al. Berberine improves cancer-derived myocardial impairment in experimental Cachexia models by targeting high-mobility group box-1[J]. Int J Mol Sci, 2024, 25(9): 4735.
Wang Y Y, Liao J, Luo Y L, et al. Berberine alleviates doxorubicin-induced myocardial injury and fibrosis by eliminating oxidative stress and mitochondrial damage via promoting nrf-2 pathway activation [J]. Int J Mol Sci, 2023, 24(4): 3257.
杨彩云, 鲁启文, 罗桑, 等. 小檗碱靶向Wnt5a/NPC1信号通路调节脂自噬抑制动脉粥样硬化形成[J]. 中国实验方剂学杂志, 2023, 29(18): 62-68.
Hu F J, Hu T, Qiao Y M, et al. Berberine inhibits excessive autophagy and protects myocardium against ischemia/ reperfusion injury via the RhoE/AMPK pathway [J]. Int J Mol Med, 2024, 53(5): 49.
张晨阳, 张琳, 杨卫利. 小檗碱及其体内代谢产物对高糖诱导大鼠H9c2心肌细胞损伤的保护作用[J]. 药物评价研究, 2024, 47(1): 68-78.
Shen Q, Yuan Y F, Li Z L, et al. Berberine ameliorates septic cardiomyopathy through protecting mitochondria and upregulating Notch1 signaling in cardiomyocytes [J]. Front Pharmacol, 2024, 15: 1502354.
Hu Y C, Chen X Y, Zhao Q M, et al. Berberine improves cardiac insufficiency through AMPK/PGC-1α signaling-mediated mitochondrial homeostasis and apoptosis in HFpEF mice [J]. Int Immunopharmacol, 2025, 155: 114613.
Wang Z C, Shao Y J, Wu F, et al. Berberine ameliorates vascular dysfunction by downregulating TMAO-endoplasmic reticulum stress pathway via gut microbiota in hypertension [J]. Microbiol Res, 2024, 287: 127824.
Wang C, Yang Y T, Chen J Y, et al. Berberine protects against high-energy and low-protein diet-induced hepatic steatosis: Modulation of gut microbiota and bile acid metabolism in laying hens [J]. Int J Mol Sci, 2023, 24(24): 17304.
Yang L X, Yu S P, Yang Y H, et al. Berberine improves liver injury induced glucose and lipid metabolic disorders via alleviating ER stress of hepatocytes and modulating gut microbiota in mice [J]. Bioorg Med Chem, 2022, 55: 116598.
Zhu Y, Li J H, Zhang P P, et al. Berberine protects hepatocyte from hypoxia/reoxygenation-induced injury through inhibiting circDNTTIP2[J]. PeerJ, 2023, 11: e16080.
Zhang Q Y, Li N, Ma X, et al. Berberine protects against gefitinib-induced liver injury by inhibiting the HMGB1/TLR4/NF-κB pathway [J]. Front Pharmacol, 2025, 16: 1645634.
Cheng J J, Yan G T, Tan W W, et al. Berberine alleviates fructose-induced hepatic injury via ADK/AMPK/Nrf2 pathway: A novel insight [J]. Biomed Pharmacother, 2024, 179: 117361.
Ali S A, Datusalia A K. Berberine attenuates ECM accumulation and the progression of acute liver failure through inhibition of NLRP3 inflammasome signalling [J]. Toxicol Appl Pharmacol, 2024, 492: 117129.
武冰, 田晓鹏, 景绍君. 小檗碱对何首乌致药物性肝损伤的保护作用[J]. 中国新药与临床杂志, 2024, 43(7): 547-551.
Wang Y Y, Zhao D, Su L Y, et al. Therapeutic potential of berberine in attenuating cholestatic liver injury: Insights from a PSC mouse model [J]. Cell Biosci, 2024, 14(1): 14.
Zhu L, Xu J J, Li H D, et al. Berberine ameliorates abnormal lipid metabolism via the adenosine monophosphate–activated protein kinase/sirtuin 1 pathway in alcohol-related liver disease [J]. Lab Investig, 2023, 103(4): 100041.
Yang S, Cao S J, Li C Y, et al. Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD [J]. J Ethnopharmacol, 2024, 332: 118354.
Ji J, Li Y, Xu T, et al. Protective effects of berberine on MASLD: Regulation of glucose and lipid metabolism through PI3K/Akt and STING pathways [J]. Naunyn Schmiedeberg's Arch Pharmacol, 2025, 398(9): 12405-12420.
Wang X K, Li H, Li J R, et al. Berberine dissociates mitochondrial complex I by SIRT3-dependent deacetylation of NDUFS1 to improve hepatocellular glucose and lipid metabolism [J]. Sci China Life Sci, 2025, 68(9): 2676-2696.
Yang H, Liu Q Q, Liu H X, et al. Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut microbiota [J]. Hepatol Commun, 2024, 8(4): e0381.
Wang S S, Lu K C, Lin L W, et al. Exploring the mechanism of berberine treatment for atherosclerosis combined with non-alcoholic fatty liver disease based on bioinformatic and experimental study [J]. PLoS One, 2024, 19(12): e0314961.
黄淡霞, 招志辉, 萧月兴, 等. 小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究[J]. 实用肝脏病杂志, 2023, 26(1): 23-26.
Zhai F G, Wang J L, Wan X Y, et al. Dual anti-inflammatory effects of curcumin and berberine on acetaminophen-induced liver injury in mice by inhibiting NF-κB activation via PI3K/AKT and PPARγ signaling pathways [J]. Biochem Biophys Res Commun, 2024, 734: 150772.
刘文娜, 霍明霞, 田立东, 等. 小檗碱预处理对大鼠肝脏移植诱发肝损伤的影响分析[J]. 实用器官移植电子杂志, 2024, 12(4): 320-324.
Tang W J, Zhang Q Q, Qin L Y, et al. M6PR upregulation by berberine attenuates hepatic senescence via sorting STING into endosome for degradation [J]. Phytomedicine, 2025, 145: 157089.
Binmahfouz L S, Hassanein E H M, Bagher A M, et al. Berberine alleviates chlorpyrifos-induced nephrotoxicity in rats via modulation of Nrf2/HO-1 axis [J]. Heliyon, 2024, 10(3): e25233.
Pan L B, Yu H, Fu J, et al. Berberine ameliorates chronic kidney disease through inhibiting the production of gut-derived uremic toxins in the gut microbiota [J]. Acta Pharm Sin B, 2023, 13(4): 1537-1553.
李光耀, 梁佳敏, 靳梦彤, 等. 小檗碱下调NF-κB p65/TGF-β1/CTGF信号通路缓解小鼠肾纤维化损伤[J]. 中国药理学通报, 2024, 40(11): 2042-2047.
陈汉文, 李吉镇, 王娜, 等. 小檗碱激活AMPK/NF-κB/TNF-α信号通路对肾病综合征大鼠肾损伤的影响[J]. 中国中西医结合肾病杂志, 2023, 24(1): 12-16.
Gong S T, Chen J Z, Zheng X H, et al. Kidney targeting and modulating macrophage polarization through AMPK signaling: Therapeutic mechanism of berberine in uric acid nephropathy [J]. Int Immunopharmacol, 2024, 138: 112632.
谢丹丹, 李含, 王白菊, 等. 小檗碱减轻慢性肾衰竭大鼠的肾脏损伤[J]. 基础医学与临床, 2024, 44(12): 1663-1669.
Zuo Z, Li Q J, Zhou S Q, et al. Berberine ameliorates contrast-induced acute kidney injury by regulating HDAC4-FoxO3a axis-induced autophagy: In vivo and in vitro [J]. Phytother Res, 2024, 38(4): 1761-1780.
Salah T M, Rabie M A, El Sayed N S. Renoprotective effect of berberine in cisplatin-induced acute kidney injury: Role of Klotho and the AMPK/mtor/ULK1/Beclin-1 pathway [J]. Food Chem Toxicol, 2025, 196: 115179.
Wang W, Yu R, Wu C, et al. Berberine alleviates contrast-induced nephropathy by activating akt/foxo3a/Nrf2 signalling pathway [J]. J Cell Mol Med, 2024, 28(1): e18016.
Li J C, Lv L X, Hu M Y, et al. Inhibition of N6-methyladenosine methylation of ASC by berberine ameliorates pyroptosis of renal tubular epithelial cells in acute kidney injury [J]. Cell Signal, 2025, 131: 111732.

2026年第57卷第15期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.15.033

接收时间：2026-03-11
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2026-03-11

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.15.033

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT